Coherus Oncology annual operating margin
2012
2013
2014
2015
2016
2017
2019
2020
2021
2022
2023
2024
2025
Coherus Oncology's operating margin was −429.51% for fiscal 2025.
View full Coherus Oncology company overview| Fiscal year | Period ended | Operating margin | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | −429.51% | +327.06 pp |
| 2024 | 2024-12-31 | −756.58% | −677.59 pp |
| 2023 | 2023-12-31 | −78.99% | +42.73 pp |
| 2022 | 2022-12-31 | −121.72% | −40.92 pp |
| 2021 | 2021-12-31 | −80.80% | −113.65 pp |
| 2020 | 2020-12-31 | 32.85% | +2.59 pp |
| 2019 | 2019-12-31 | 30.27% | +14949.03 pp |
| 2017 | 2017-12-31 | −14,918.77% | −14857.58 pp |
| 2016 | 2016-12-31 | −61.19% | +668.04 pp |
| 2015 | 2015-12-31 | −729.23% | −521.29 pp |
| 2014 | 2014-12-31 | −207.94% | +1100.42 pp |
| 2013 | 2013-12-31 | −1,308.36% | +719.97 pp |
| 2012 | 2012-12-31 | −2,028.33% | — |
| Fiscal quarter | Period ended | Operating margin | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | −225.98% | +217.61 pp |
| Q1 2026 | 2026-03-31 | −293.67% | +304.24 pp |
| Q4 2025 | 2025-12-31 | −359.90% | +226.99 pp |
| Q3 2025 | 2025-09-30 | −383.14% | +391.08 pp |
| Q2 2025 | 2025-06-30 | −443.59% | −58.72 pp |
| Q1 2025 | 2025-03-31 | −597.91% | +2339.14 pp |
| Q4 2024 | 2024-12-31 | −586.89% | −511.60 pp |
| Q3 2024 | 2024-09-30 | −774.22% | −731.30 pp |
| Q2 2024 | 2024-06-30 | −384.87% | −326.04 pp |
| Q1 2024 | 2024-03-31 | −2,937.05% | −2728.19 pp |
| Q4 2023 | 2023-12-31 | −75.29% | +38.25 pp |
| Q3 2023 | 2023-09-30 | −42.92% | +134.18 pp |
| Q2 2023 | 2023-06-30 | −58.83% | +14.34 pp |
| Q1 2023 | 2023-03-31 | −208.86% | −74.24 pp |
| Q4 2022 | 2022-12-31 | −113.54% | −59.64 pp |
| Q3 2022 | 2022-09-30 | −177.11% | −137.37 pp |
| Q2 2022 | 2022-06-30 | −73.17% | −45.60 pp |
| Q1 2022 | 2022-03-31 | −134.62% | +66.94 pp |
| Q4 2021 | 2021-12-31 | −53.90% | −68.78 pp |
| Q3 2021 | 2021-09-30 | −39.74% | −69.43 pp |
| Q2 2021 | 2021-06-30 | −27.57% | −75.71 pp |
| Q1 2021 | 2021-03-31 | −201.56% | −236.73 pp |
| Q4 2020 | 2020-12-31 | 14.88% | −21.48 pp |
| Q3 2020 | 2020-09-30 | 29.69% | −16.73 pp |
| Q2 2020 | 2020-06-30 | 48.14% | +15.19 pp |
| Q1 2020 | 2020-03-31 | 35.18% | +79.92 pp |
| Q4 2019 | 2019-12-31 | 36.36% | +4094.78 pp |
| Q3 2019 | 2019-09-30 | 46.42% | +4091.99 pp |
| Q2 2019 | 2019-06-30 | 32.95% | +45012.46 pp |
| Q1 2019 | 2019-03-31 | −44.74% | +34282.36 pp |
| Q3 2017 | 2017-09-30 | −4,058.42% | −4110.39 pp |
| Q2 2017 | 2017-06-30 | −4,045.57% | −3599.62 pp |
| Q1 2017 | 2017-03-31 | −44,979.50% | −44458.81 pp |
| Q4 2016 | 2016-12-31 | −34,327.10% | −33469.33 pp |
| Q3 2016 | 2016-09-30 | 51.96% | +684.46 pp |
| Q2 2016 | 2016-06-30 | −445.95% | — |
| Q1 2016 | 2016-03-31 | −520.69% | — |
| Q2 2015 | 2015-06-30 | −857.78% | — |
| Q1 2015 | 2015-03-31 | −632.50% | — |
Over the last five reported fiscal years, Coherus Oncology's operating margin decreased from 32.85% to −429.51%, a change of −462.36 percentage points. The latest reported quarter, Q2 2026, shows −225.98%.
Operating margin measures the percentage of revenue left after operating costs and expenses. It shows how much operating profit a company generates from each dollar of revenue.
TickerStat calculates operating margin as SEC-reported operating income divided by SEC-reported revenue for the same fiscal period. Changes are shown in percentage points. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Coherus Oncology filings at SEC.gov ↗